Temozolomide and oral etoposide in children with recurrent malignant brain tumors

Article Details

Authors
Antonio Ruggiero MD, Anna Ariano MD, Silvia Triarico MD, Michele Antonio Capozza MD, Alberto Romano MD, Palma Maurizi MD, Stefano Mastrangelo MD, Giorgio Attinà MD

Article Type
Review

DOI
10.7573/dic.2020-3-1

Related Articles

Article Page

Abstract

Despite advances in the treatment of brain tumors, the prognosis of children with recurrent malignant brain tumors remains poor. Etoposide (VP-16), an inhibitor of nuclear enzyme deoxyribonucleic acid (DNA)-topoisomerase II, has shown activity in brain tumors. Its efficacy appears schedule dependent but, to date, the most effective schedule of administration has not been well defined. Temozolomide (TMZ), like VP-16, penetrates the blood–brain barrier and has activity against malignant brain tumors. This novel alkylating agent is rapidly absorbed and is highly bioavailable after oral administration. The antitumor activity of TMZ has been shown to be schedule dependent. Based on the evidence of different mechanisms of cytotoxicity, TMZ and VP-16 have been utilized in combination in patients with malignant brain tumors. This review evaluates the results derived from the combination use of TMZ and oral VP-16. The reported data suggest potential activity of oral VP-16 and TMZ alone or in combination. Further clinical trials are needed to explore and confirm their promising activity in relapsed brain neoplasms.

Keywords: etoposide, glioma, medulloblastoma, recurrent brain tumor, temozolomide.

Citation: Ruggiero A, Ariano A, Triarico S, Capozza MA, Romano A, Maurizi P, Mastrangelo S, Attinà G. Temozolomide and oral etoposide in children with recurrent malignant brain tumors. Drugs in Context 2020; 9: 2020-3-1. DOI: 10.7573/dic.2020-3-1

Contributions: All authors contributed equally to the preparation of this review. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/05/dic.2020-3-1-COI.pdf

Acknowledgements: This work was technically supported by ‘Sara un angelo con la bandana Onlus.’ We thank them for their dedicated patient care.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2020 Ruggiero A, Ariano A, Triarico S, Capozza MA, Romano A, Maurizi P, Mastrangelo S, Attinà G. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2020 Ruggiero A, Ariano A, Triarico S, Capozza MA, Romano A, Maurizi P, Mastrangelo S, Attinà G. https://doi.org/10.7573/dic.2020-3-1. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/temozolomide-and-oral-etoposide-in-children-with-recurrent-malignant-brain-tumors

Correspondence: Antonio Ruggiero (ORCID 0000-0002-6052-3511), Paediatric Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy. antonio.ruggiero@unicatt.it

Provenance: submitted; externally peer reviewed.

Submitted: 9 March 2020; Peer review comments to author: 28 April 2020; Revised manuscript received: 1 May 2020; Accepted: 8 May 2020; Publication date: 2 June 2020.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF